Human CellExp KLK-7 / Kallikrein-7, human recombinant protein
KLK7, Kallikrein-7, PRSS6, SCCE, hK7, hSCCE
|Calculated MW||This protein is fused with polyhistidine tag at the C-terminus, and has a calculated MW of 26.1 kDa. The predicted N-terminus is Glu 23. DTT-reduced Protein migrates as 29-33 kDa in SDS-PAGE due to glycosylation.|
|Other Names||KLK7, Kallikrein-7, PRSS6, SCCE, hK7, hSCCE|
|Results||>130 pmoles / min / µg|
|Sequence||Glu 23 – Arg 253|
|Target/Specificity||KLK-7 / Kallikrein-7|
|Application Notes||Centrifuge the vial prior to opening. Reconstitute in PBS, pH 7.4. Do not vortex.|
|Storage||-20°C; Lyophilized from 0.22 µm filtered solution in 50 mM Tris, 150 mM NaCl, pH 7.5. Normally Mannitol or Trehalose are added as protectants before lyophilization.|
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Kallikrein-7 (KLK7) is also known as kallikrein-related peptidase 7, Stratum corneum chymotryptic enzyme, Serine protease 6, KLK7, and PRSS6, is a secreted protein which belongs to the peptidase S1 family and Kallikrein subfamily. KLK7 is secreted as an inactive zymogen in the stratum granulosum layer of the epidermis, requiring proteolytic cleavage of the short N-terminal pro-region to liberate activated enzyme. This may be performed by KLK5 or matriptase, which are in vitro activators of KLK7. Once active, KLK7 is able to cleave desmocollin and corneodesmosin. KLK7 activity is regulated by a number of endogenous protein inhibitors including LEKTI, SPINK6, elafin and alpha-2-Macroglobulin-like 1. Both Zn2+ and Cu2+ ions are also able to inhibit KLK7. Dysregulation of KLK7 has been linked to several skin disorders, and overexpression of KLK7 may provide a route for metastasis in several cancers.
Hansson L.,et al.J. Biol. Chem. 269:19420-19426(1994).
Yousef G.M.,et al.Gene 254:119-128(2000).
Gan L.,et al.Gene 257:119-130(2000).
Hansson L.,et al.J. Invest. Dermatol. 118:444-449(2002).
Dong Y.,et al.Clin. Cancer Res. 9:1710-1720(2003).
If you have any additional inquiries please email technical services at firstname.lastname@example.org.